Alice Melao,  —

Flex Pharma’s New CEO William McVicar to Continue Developing CMT Therapy Candidate FLX-787

Flex Pharma’s board of directors has named William McVicar, PhD, as the company’s new president and chief executive officer. McVicar will continue supporting the company’s development of new therapies to treat muscle cramps and spasticity associated with serious neurological conditions. The company also announced updated development plans…

Japanese Study Describes 15 New Variants of MFN2 Gene in Group of Charcot-Marie-Tooth Patients

Charcot–Marie–Tooth (CMT) disease type 2, or axonal CMT, has long been associated with genetic variants of the MFN2 gene, which encodes a protein of the mitochondrial outer membrane. A Japanese study now finds that these mutations may also be related to demyelinating CMT subtype (type 1), which could help explain the different clinical…